19 results about "Retinoic acid" patented technology

The present application relates to the technical field of cosmetic raw materials, and provides tocopheryl retinoate and application thereof in cosmetics and / or skin care products. The tocopheryl retinoate introduces a tocopherol group with antioxidant activity into the molecular structure of retinoic acid, significantly improves the light stability and thermal stability of the compound while maintaining the biological activity of vitamin A ingredients, and effectively reduces the irritation to the skin. The tocopheryl retinoate is suitable for the cosmetic and / or skin care product system used in the daytime, can improve the skin condition, repair the skin barrier and protect the skin, and has good safety and wide application prospect.

The present invention relates to a conjugate compound comprising 13-cis-retinoic acid and vitamin C, and its pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The present compound has a much better water solubility than that of retinoic acid, and thus reduces an effective dosage of retinoic acid and minimizes side effect. The present compound increases the efficiency and concentration of 13-cis-retinoic acid to across the cell membrane into the cell. The present compound is useful in treating cancer such as pancreatic cancer.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

This invention discloses a solvate of rememega-2 and its preparation method. The rememega-2 solvate (compound II) provided by this invention has a purity of up to 99.15% compared with the existing rememega-2 methyl tert-butyl ether solvate. The preparation method includes the following steps: adding crude rememega-2 to a binary solvent, heating to 45℃~75℃, adding an antisolvent, stirring, crystallizing, cooling and filtering, and drying under reduced pressure to obtain rememega-2 solvate (compound II). Then, placing rememega-2 solvate (compound II) in ethanol and stirring to obtain rememega-2 (compound I). This route is simple to operate, the process is stable, and it is easy to scale up. Moreover, the rememega-2 (compound I) prepared by this solvate (compound II) has a purity of up to 99.66%, which is higher than that of rememega-2 (compound I) prepared by the existing rememega-2 methyl tert-butyl ether solvate. It also has better fluidity, does not caking, is easy to transfer, and is convenient for later production.

This invention discloses a method for synthesizing an intermediate of retinoic acid, relating to the field of pharmaceutical organic synthesis technology, comprising the following steps: S1, in the presence of a base, 2-amino-3-chloropyridine and 4-bromopiperidine undergo a nucleophilic substitution reaction in solvent A to prepare compound III; S2, in the presence of a catalyst and ammonia solution, compound III undergoes an amination reaction in solvent B to prepare compound II; S3, compound II is dissolved in solvent C, and sequentially undergoes CDI cyclization and hydrogen chloride solution salt formation to prepare compound I, namely 1-(piperidin-4-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one. This invention is low-cost, uses mild reaction conditions, has a simple synthesis process, high yield, and eliminates the need for expensive and potentially unsafe excipients, effectively improving reaction safety, being environmentally friendly, and suitable for industrial production.

This invention, entitled "A Method and Product for Pretreatment of Mesenchymal Stem Cells and Its Application in Stroke Drugs," belongs to the field of biotechnology. The technical problem to be solved is to improve the function and therapeutic effect of mesenchymal stem cells. The key technical solution is a method for pretreatment of mesenchymal stem cells, including: culturing cells using an activation medium, culturing cells using a directional medium, and culturing cells under hypoxic conditions using an adaptation medium; the activation medium contains complete medium, IFN-γ, TNF-α, and IL-1β; the directional medium contains complete medium, sodium valproate, 5-azacytidine, and all-trans retinoic acid; the adaptation medium is a complete medium containing basal medium and free of animal serum. The pretreatment method of this invention enhances the anti-inflammatory, neuroprotective, and angiogenic capabilities of mesenchymal stem cells, showing significant therapeutic effects on stroke, and since it does not use animal serum, it meets clinical requirements.

The application discloses a kind of serum-free epidermal melanocyte culture medium and its application, method includes by dissolving adenine, hepatocyte growth factor (HGF), glutamine, retinoic acid, vitamin E, nicotinic acid, sodium selenite, sodium hyaluronate and recombination human type XVII collagen are configured into initial culture medium;Preparation of melanocyte stimulating hormone, endothelin-3, transferrin, triiodothyronine, cholesterol, neuroregulin 1 (NRG1), 3-isobutyl-1-methyl purine (IBMX), dibutyryl cyclic adenosine monophosphate (db-cAMP), cholera toxin, hydrocortisone and recombination human insulin mother liquor;Step three: according to culture and concentration, a certain amount of mother liquor of step two is added to initial culture medium.The culture medium can effectively promote human epidermal melanocyte proliferation, melanin accumulation and help to promote human umbilical cord mesenchymal stem cells into human epidermal melanocyte, provide key advantage for obtaining functional melanocyte with high activity and therapeutic potential.

This invention provides a circRNA-LNP delivery system for in vivo induction of iTregs, its preparation method, and its applications. The delivery system includes circRNA encoding human TGF-β1, lipid nanoparticles encapsulating the circRNA, and IL-2 modified on the surface of the lipid nanoparticles. This invention synergistically combines retinoic acid as a functional immunomodulatory small molecule with five lipids, significantly improving the uptake efficiency of Treg precursor cells and the induction efficiency of iTregs. It can also efficiently increase the proportion of functional iTregs in diseased tissues in vivo, demonstrating excellent therapeutic effects on immunomodulatory diseases such as ulcerative colitis, and providing a novel technical pathway for the radical treatment of autoimmune and inflammatory diseases.

Provided are a pharmaceutical combination and the use thereof in the treatment of acne. The pharmaceutical combination contains an antiandrogen, a retinoic acid drug and an antibacterial drug. The pharmaceutical combination has a synergistic effect in the treatment of acne.

The application provides a drug-loaded gelatin nanogel, a biomimetic nanogel and a preparation method and combined drug and use thereof, and belongs to the technical field of biological medicines.The application forms a drug-loaded gelatin nanogel by reacting all-trans retinoic acid with pirfenidone and gelatin, cooperatively inhibits the activation of pancreatic stellate cells and blocks the pro-fibrosis signal pathway, realizes the reversal of the fibrosis microenvironment of pancreatic cancer, coats the drug-loaded gelatin nanogel on the membrane of activated pancreatic stellate cells to construct a biomimetic nanogel, so that the biomimetic nanogel has active targeting, and the drug delivery efficiency and the treatment effect are significantly improved, and the drug-loaded gelatin nanogel, the biomimetic nanogel and a chemotherapeutic drug are combined to treat pancreatic cancer, have a significant anti-tumor effect, and the combined treatment of the biomimetic nanogel and gemcitabine has a synergistic anti-tumor effect.The gelatin realizes effective regulation of the dense fibrosis microenvironment of pancreatic cancer, and provides a new feasible strategy for the treatment of pancreatic cancer.

A retinoic acid prodrug to which a boron functional group having a structure represented by chemical formula 1 is bound is described. The retinoic acid prodrug self-assembles to form nanoparticles. Therefore, an anticancer drug composition comprises the same as an active ingredient. According to the retinoic acid prodrug, targeted therapy of tumor cells is possible through the synergistic anticancer effect of retinoic acid and the boron functional group and the surface modification of particles. In particular, the retinoic acid prodrug enables a drug loading of 100 wt %, and thus can provide an effective anticancer drug.

This invention provides a method for preparing an intermediate of retinoic acid, belonging to the field of compound preparation technology. The preparation method includes the following steps: (1) compound M6 and R (1) The tert-butylsulfinamide reaction yields compound M6A; (2) Compound M6A undergoes a reduction reaction under the action of a reducing agent to yield (9R)-6,7,8,9-tetrahydro-9-hydroxy-5H-cycloheptane[b]pyridine-5-amine. The preparation method of the present invention avoids the use of high-pressure hydrogenation and ammonia, resulting in less environmental pollution and a higher yield, which facilitates subsequent industrial production.

Disclosed herein are personal care compositions. More particularly, disclosed herein is a cosmetic composition containing resorcinol, a functionalized heteroaromatic compound, and retinoic acid precursor in combination with antioxidant, compatible oil, and low HLB, high molecular weight emulsifier to provide for improved stability of the oil-continuous composition.

This invention provides a nanoformulation capable of enhancing the immune response to in situ tumor vaccines. The nanoformulation comprises zoledronic acid, all-trans retinoic acid, and metal ions. Preferably, the metal ion is a lanthanide metal, such as Gd. 3+ Preferred, zoledronic acid: Gd 3+ The mass ratio of all-trans retinoic acid is 4:1:5. The nano-formulation consists of zoledronic acid and Gd... 3+ Zol / Gd-NPs nanocoagulation polymers were formed by mixing in water. All-trans retinoic acid was dissolved in anhydrous ethanol to prepare albumin-encapsulated nanoparticles (A-NPs), which were then mixed with the Zol / Gd-NPs nanocoagulation polymers and sonicated to obtain the final product. These nanoparticles, on the one hand, can utilize zoledronic acid to eliminate macrophages, thereby reversing the inhibition of intratumoral dendritic cells (DCs) by the tumor immunosuppressive microenvironment; on the other hand, all-trans retinoic acid can significantly increase the expression of MHC-I and tumor antigens in tumor cells, thus ensuring the activation of CD8. + T cells can effectively recognize and kill tumors, generating a systemic anti-tumor immune response.

This invention relates to a method for preparing an intermediate of retinoic acid, belonging to the field of medicinal chemistry technology. The preparation method includes the following steps: Compound II is reduced at low temperature in an inert gas organic solvent in the presence of a catalyst and a reducing agent; after post-treatment to resolve into a salt, compound I is then obtained by free separation. This invention uses a chiral oxazolium borane catalyst, which can easily obtain the target product with high purity, avoids the use of hydrogen, is simple and safe to operate, has a high yield, and relatively low cost, making it more conducive to production implementation. The reaction process is as follows:

This invention relates to a retinoic acid-alcohol amine complex, which is composed of retinoic acid and an alcohol amine compound. It is in liquid form at room temperature and has good water solubility / water dilution resistance and skin penetration effect. It overcomes the limitations of retinoic acid compounds in the field of pharmaceutical application in the prior art and has broad pharmaceutical prospects.

This invention relates to a novel application of all-trans retinoic acid combined with a cyclooxygenase inhibitor in the treatment of prostate cancer. The all-trans retinoic acid is used to regulate gene expression and metabolic processes in tumor cells, promoting cell differentiation and tumor suppressor signaling pathways. The cyclooxygenase inhibitor is used to inhibit prostaglandin production induced by all-trans retinoic acid treatment. The cyclooxygenase inhibitor includes small molecule compounds that specifically inhibit / antagonize cyclooxygenase, interfering molecules that specifically interfere with cyclooxygenase gene expression, gene-editing reagents that specifically knock out the cyclooxygenase gene, reagents that downregulate / lose the function of cyclooxygenase, or antibodies that specifically bind to cyclooxygenase. The advantages are: it reveals that the combination of all-trans retinoic acid and a cyclooxygenase inhibitor reduces the immunosuppressive microenvironment in the tumor during prostate cancer treatment, thereby enhancing the tumor-suppressive effect and strengthening anti-tumor immunity.

The application discloses application of a RIG-I inhibitor in myocardial ischemia-reperfusion injury. By conditionally knocking out a RIG-I gene in myocardial cells, it is found that RIG-I protein in myocardial cells participates in and relieves myocardial ischemia-reperfusion injury of mice, and it is determined that retinoic acid-inducible gene I (RIG-I, also known as DDX58) is a key treatment target. Further, by computer-aided drug design, a RIG-I specific small molecule inhibitor RI-Q1 is screened and obtained, and it is proved that the small molecule inhibitor can effectively inhibit pyroptosis inflammation of myocardial cells, thereby preventing or treating MI / RI. The small molecule inhibitor RI-Q1 is easy to obtain, can directly inhibit RIG-I protein activity, and significantly reduces pyroptosis and inflammatory reaction of myocardial cells. Therefore, as a novel small molecule compound targeting RIG-I, the small molecule inhibitor RI-Q1 provides a new drug development direction and application prospect for treatment of MI / RI.